Cargando…
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study
BACKGROUND: The XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events (N = 6784). HYPOTHESIS: Because previous real‐world studies have not reporte...
Autores principales: | Camm, A. John, Amarenco, Pierre, Haas, Sylvia, Bach, Miriam, Kirchhof, Paulus, Kuhls, Silvia, Lambelet, Marc, Turpie, Alexander G.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724214/ https://www.ncbi.nlm.nih.gov/pubmed/32896928 http://dx.doi.org/10.1002/clc.23452 |
Ejemplares similares
-
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016) -
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014) -
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020) -
XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America
por: Martínez, Carlos Arturo Areán, et al.
Publicado: (2018) -
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry
por: Pisters, R., et al.
Publicado: (2017)